

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

ANNOUNCEMENT

APPROVAL TO COMMERCIALISE PRESERVATIVE-FREE SINGLE-DOSE TOBRAMYCIN EYE DROPS IN CHINA

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors (“**Board**”) of Essex Bio-Technology Limited (“**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that 珠海億勝生物製藥有限公司 (Zhuhai Essex Bio-Pharmaceutical Company Limited*), an indirect wholly-owned subsidiary of the Company, has obtained an approval from 國家食品藥品監督管理總局 (China Food and Drug Administration) for the commercialisation of the preservative-free single-dose Tobramycin Eye Drops (妥布霉素滴眼液) (“**Approved Product**”) in the People’s Republic of China. The Group is currently in preparation for applying from 廣東省食品藥品監督管理局 (Guangdong Provincial Food and Drug Administration) of a GMP 認證 (Certificate of Good Manufacturing Practices*), and following obtaining such certificate, the Approved Product is expected to be launched in the market at or around the end of 2017.

The Approved Product is the Group's first single-dose eye drops product, out of the eight single-dose eye drops products within the research and development pipeline, and is a preservative-free ophthalmic anti-infective product. The Board believes that the Approved Product will boost the Group's competitive position in the eye care industry.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 13 June 2017

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.

* *For identification purpose only*